<DOC>
	<DOCNO>NCT00273546</DOCNO>
	<brief_summary>- 1.To compare overall survival treatment test tri-therapy ( TPF : docetaxel plus cisplatin 5FU ) control treatment ( PF : cisplatin plus 5-FU ) follow chemoradiotherapy patient locally advanced SCCHN . - 2.The main secondary endpoint progression free survival ( PFS ) . The secondary endpoint evaluate compare improvement local symptom ; time-to-treatment failure ; quality life ; clinical complete response rate ( CR CR/PR ) ; toxicity evaluate relationship tumor marker response therapy .</brief_summary>
	<brief_title>Induction Chemotherapy Comparing Taxotere® Cisplatin 5-Fluorouracil ( TPF ) With Standard Cisplatin 5-Fluorouracil ( PF ) Followed Chemoradiation Locally Advanced Head Neck Cancer</brief_title>
	<detailed_description />
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>1.Histologically cytologically proven squamous cell carcinoma head/neck . 2.Primary tumor site eligible : oral cavity , oropharynx , hypopharynx , larynx . Although admittedly squamous cell type , follow tumor exclude responsiveness chemotherapy may differ : nasal , paranasal cavity ; nasopharynx . 3.Stage 3 4 disease without evidence distant metastasis verify Chest XRay , abdominal ultrasound CT ( liver function test abnormality ) ; bone scan case local symptom . 4.At least one uni bidimensionally measurable lesion . 5.Tumor consider inoperable evaluation multidisciplinary team ( surgeon , medical oncologist radiation oncologist ) . Criteria include : Technical unresectablilityie tumor fixation/invasion base skull cervical vertebra involvement nasopharynx fix lymph node ; Physician 's decision base low surgical curability include T34 stage , N23 stag exclude T1N2 ; organ preservation . 6.No previous chemotherapy radiotherapy reason previous surgery SCCHN ( biopsy ) allow time study entry . 7.Age ³ 18 year . 8.WHO performance status 01 9.No active alcohol addiction 10.Life expectancy ³ 12 week 11.Signed informed consent prior begin protocol specific procedures 12.Adequate bone marrow , hepatic renal function evidence follow : Hematology ( Bone Marrow ) : Neutrophil count ³ 2.0 x 10 9/L ; Platelet count ³ 100 X 10 9/L ; Hemoglobin ³ 10g/dL ; Hepatic function : Total bilirubin WNL ; ASAT ( SGOT ) ALAT ( SGPT ) £ 2.5 X ULN ; Alkaline phosphatase £ 5 X ULN ; patient ASAT ALAT &gt; 1.5 x ULN associate alkaline phosphatase &gt; 2.5 x ULN eligible study ; Renal function : creatinine clearance ³ 60 ml/min ( actual calculate CockcroftGault method follow : Weight ( kg ) X ( 140age ) /K x serum creatinine . 13.Patients must available treatment follow . Patients register trial must treat follow participate center . 1.Pregnant lactate woman woman childbearing potential use adequate contraception . 2.Previous current malignancy site , exception adequately treat situ carcinoma cervix uterus , basal squamous cell carcinoma skin cancer curatively treat surgery evidence disease least 5 year . Any prior treatment radiotherapy chemotherapy exclusion criterion . 3.Symptomatic peripheral neuropathy ³ grade 2 NCICCTG criterion . 4.Symptomatic alter hearing &gt; grade 2 NCICCTG criterion . 5.Other serious illness medical condition include limited : Unstable cardiac disease despite treatment , myocardial infarction within 6 month prior study entry ; History significant neurologic psychiatric disorder include dementia seizure ; Active uncontrolled infection ; Active peptic ulcer ; Hypercalcemia ; Chronic obstructive pulmonary disease require hospitalization year precede study entry . 6.Patients require intravenous alimentation . 7.Patients experience weight loss 20 % body weight 3 month precede study entry . 8.Concurrent treatment anticancer therapy 9.Participation investigational trial within 30 day study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Head Neck Cancer</keyword>
	<keyword>Induction</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Chemoradiotherapy</keyword>
</DOC>